Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 841 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection... April 19, 2024 ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 Load more HOT NEWS Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... Researchers Have Harnessed a Compound from a Common Plant Called Feverfew... Why do non-smokers face delays in getting a lung cancer diagnosis?
